(Reuters) – Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and […]

VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss […]

VENICE, ITALY — Personalized doses and slow tapering of semaglutide (Wegovy or Ozempic, Novo Nordisk) in patients who also follow a digital weight loss program can […]

NEW ORLEANS — Adrenalectomy for the treatment of mild autonomous cortisol secretion (MACS) appears to improve bone quality but not bone density, new data suggested. Formerly […]

Self-perceived weight as a 10-year-old may influence risks for all-cause mortality and incident cardiovascular disease (CVD) in adults who are overweight or obese, research presented on […]

The daily injectable vosoritide (Voxzogo) appears promising for various genetic causes of short stature in children, new phase 2 trial data suggested. Vosoritide is a C-type […]

Food and drink advertisements on video game live-streaming platforms (VGLSPs) such as Twitch are associated with a greater preference for and consumption of products high in […]

NEW ORLEANS — Children and adults with congenital adrenal hyperplasia (CAH) often receive supraphysiologic doses of glucocorticoids, resulting in adverse effects while at the same time […]

NEW ORLEANS — When using tirzepatide (Zepbound, Eli Lilly) to treat obesity, patience may pay off.  New post hoc data from Lilly’s SURMOUNT-1 trial of people […]